XOMA Royalty (XOMA)
Market Price (2/6/2026): $24.9 | Market Cap: $302.2 MilSector: Health Care | Industry: Biotechnology
XOMA Royalty (XOMA)
Market Price (2/6/2026): $24.9Market Cap: $302.2 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 7.2%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 3.1% | Weak multi-year price returns2Y Excs Rtn is -18%, 3Y Excs Rtn is -44% | Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 55x |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 78% | Weak revenue growthRev Chg QQuarterly Revenue Change % is -28% | |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 44%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 43% | Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 60% | |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -34% | Key risksXOMA key risks include [1] the potential failure of its partners' early-stage clinical assets, Show more. | |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 7.2%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 3.1% |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 78% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 44%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 43% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -34% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -18%, 3Y Excs Rtn is -44% |
| Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 55x |
| Weak revenue growthRev Chg QQuarterly Revenue Change % is -28% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 60% |
| Key risksXOMA key risks include [1] the potential failure of its partners' early-stage clinical assets, Show more. |
Qualitative Assessment
AI Analysis | Feedback
XOMA Royalty (XOMA) stock has lost about 25% since 10/31/2025 because of the following key factors:
1. Disappointing Q3 2025 Financial Results.
XOMA Royalty reported its third-quarter 2025 earnings on November 12, 2025, with an Earnings Per Share (EPS) of -$0.35, significantly missing the consensus analyst estimate of -$0.02. Additionally, quarterly revenue came in at $9.35 million, falling short of analyst expectations of $11.47 million. This substantial miss on both profitability and revenue likely contributed to a decline in investor confidence.
2. Analyst Price Target Adjustments.
On December 11, 2025, Leerink Partners maintained its "Outperform" rating for XOMA Royalty but notably lowered its price target from $58.00 to $45.00. While some analysts maintained "Buy" ratings with higher targets, this specific downward adjustment in a price target from a research firm suggests a more cautious outlook on the stock's near-term potential, which can negatively influence market sentiment.
Show more
1. Disappointing Q3 2025 Financial Results.
XOMA Royalty reported its third-quarter 2025 earnings on November 12, 2025, with an Earnings Per Share (EPS) of -$0.35, significantly missing the consensus analyst estimate of -$0.02. Additionally, quarterly revenue came in at $9.35 million, falling short of analyst expectations of $11.47 million. This substantial miss on both profitability and revenue likely contributed to a decline in investor confidence.
2. Analyst Price Target Adjustments.
On December 11, 2025, Leerink Partners maintained its "Outperform" rating for XOMA Royalty but notably lowered its price target from $58.00 to $45.00. While some analysts maintained "Buy" ratings with higher targets, this specific downward adjustment in a price target from a research firm suggests a more cautious outlook on the stock's near-term potential, which can negatively influence market sentiment.
Show more
Stock Movement Drivers
Fundamental Drivers
The -24.4% change in XOMA stock from 10/31/2025 to 2/5/2026 was primarily driven by a -22.4% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 2052026 | Change |
|---|---|---|---|
| Stock Price ($) | 32.98 | 24.92 | -24.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 13 | 13 | -1.6% |
| P/S Multiple | 31.0 | 24.1 | -22.4% |
| Shares Outstanding (Mil) | 12 | 12 | -1.1% |
| Cumulative Contribution | -24.4% |
Market Drivers
10/31/2025 to 2/5/2026| Return | Correlation | |
|---|---|---|
| XOMA | -24.4% | |
| Market (SPY) | -0.7% | 12.8% |
| Sector (XLV) | 7.3% | 10.7% |
Fundamental Drivers
The 0.2% change in XOMA stock from 7/31/2025 to 2/5/2026 was primarily driven by a 5.4% change in the company's P/S Multiple.| (LTM values as of) | 7312025 | 2052026 | Change |
|---|---|---|---|
| Stock Price ($) | 24.88 | 24.92 | 0.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 13 | 13 | -3.7% |
| P/S Multiple | 22.8 | 24.1 | 5.4% |
| Shares Outstanding (Mil) | 12 | 12 | -1.4% |
| Cumulative Contribution | 0.2% |
Market Drivers
7/31/2025 to 2/5/2026| Return | Correlation | |
|---|---|---|
| XOMA | 0.2% | |
| Market (SPY) | 7.5% | 18.8% |
| Sector (XLV) | 19.3% | 27.0% |
Fundamental Drivers
The -6.4% change in XOMA stock from 1/31/2025 to 2/5/2026 was primarily driven by a -25.0% change in the company's P/S Multiple.| (LTM values as of) | 1312025 | 2052026 | Change |
|---|---|---|---|
| Stock Price ($) | 26.61 | 24.92 | -6.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 10 | 13 | 29.4% |
| P/S Multiple | 32.1 | 24.1 | -25.0% |
| Shares Outstanding (Mil) | 12 | 12 | -3.5% |
| Cumulative Contribution | -6.4% |
Market Drivers
1/31/2025 to 2/5/2026| Return | Correlation | |
|---|---|---|
| XOMA | -6.4% | |
| Market (SPY) | 13.6% | 29.2% |
| Sector (XLV) | 6.8% | 28.1% |
Fundamental Drivers
The 22.8% change in XOMA stock from 1/31/2023 to 2/5/2026 was primarily driven by a 272.4% change in the company's Net Income Margin (%).| (LTM values as of) | 1312023 | 2052026 | Change |
|---|---|---|---|
| Stock Price ($) | 20.29 | 24.92 | 22.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 40 | 13 | -69.0% |
| Net Income Margin (%) | 46.2% | 172.2% | 272.4% |
| P/E Multiple | 12.4 | 14.0 | 12.6% |
| Shares Outstanding (Mil) | 11 | 12 | -5.7% |
| Cumulative Contribution | 22.8% |
Market Drivers
1/31/2023 to 2/5/2026| Return | Correlation | |
|---|---|---|
| XOMA | 22.8% | |
| Market (SPY) | 72.9% | 21.8% |
| Sector (XLV) | 21.5% | 22.3% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| XOMA Return | -53% | -12% | 1% | 42% | 1% | 1% | -39% |
| Peers Return | 18% | -28% | -10% | 22% | 66% | 9% | 69% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 1% | 83% |
Monthly Win Rates [3] | |||||||
| XOMA Win Rate | 33% | 42% | 50% | 67% | 50% | 50% | |
| Peers Win Rate | 54% | 46% | 46% | 46% | 71% | 100% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| XOMA Max Drawdown | -55% | -24% | -25% | 0% | -29% | -7% | |
| Peers Max Drawdown | -14% | -33% | -29% | -7% | -5% | -0% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: RPRX, LGND.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/5/2026 (YTD)
How Low Can It Go
| Event | XOMA | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -68.7% | -25.4% |
| % Gain to Breakeven | 219.3% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -47.4% | -33.9% |
| % Gain to Breakeven | 90.0% | 51.3% |
| Time to Breakeven | 243 days | 148 days |
| 2018 Correction | ||
| % Loss | -69.4% | -19.8% |
| % Gain to Breakeven | 226.4% | 24.7% |
| Time to Breakeven | 718 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -91.1% | -56.8% |
| % Gain to Breakeven | 1023.7% | 131.3% |
| Time to Breakeven | Not Fully Recovered days | 1,480 days |
Compare to RPRX, LGND
In The Past
XOMA Royalty's stock fell -68.7% during the 2022 Inflation Shock from a high on 1/1/2021. A -68.7% loss requires a 219.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About XOMA Royalty (XOMA)
XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
AI Analysis | Feedback
- Like a music publishing company, but for drug royalties instead of songs.
- Like a Real Estate Investment Trust (REIT) such as Prologis (PLD) or Simon Property Group (SPG), but for drug royalties instead of physical properties.
AI Analysis | Feedback
- Royalty Streams: Financial interests that provide XOMA with a percentage of future sales from various approved pharmaceutical products developed and marketed by third-party companies.
- Milestone Payments: Economic rights that entitle XOMA to receive payments upon the achievement of pre-defined development or regulatory milestones for drug candidates developed by other companies.
AI Analysis | Feedback
XOMA Royalty (XOMA) sells primarily to other companies. Its major "customers" are the pharmaceutical companies that commercialize the products from which XOMA holds royalty interests. These companies pay royalties to XOMA based on the sales of those products.
The major customer companies, along with their symbols if publicly traded, include:
- F. Hoffmann-La Roche AG (OTCQX: RHHBY) - (via its subsidiary Genentech, Inc., for VABYSMO®)
- Eli Lilly and Company (NYSE: LLY) - (for RETEVMO®)
- Johnson & Johnson (NYSE: JNJ) - (via its subsidiary Janssen Biotech, Inc., for STELARA®)
- AbbVie Inc. (NYSE: ABBV) - (for certain biologic products related to the STELARA® royalty stream)
- Sumitomo Pharma Co., Ltd. (TYO: 4506; OTC: DNPUF) - (via its subsidiary Urovant Sciences, Inc., for GEMTESA®)
- Mayne Pharma Group Limited (ASX: MYX) - (for IMVEXXY®)
- Bausch Health Companies Inc. (NYSE: BHC) - (via its subsidiary Salix Pharmaceuticals, Inc., for GOLYTELY®)
- Norgine B.V. (private company) - (for MOVIPREP®)
AI Analysis | Feedback
null
AI Analysis | Feedback
Owen Hughes, Chief Executive Officer Owen Hughes was appointed full-time Chief Executive Officer of XOMA Royalty in January 2024, after serving as Executive Chairman of the Board and Interim Chief Executive Officer since January 2023. He has served as CEO of Sail Bio, Inc., a private biotechnology company, since February 2022. Mr. Hughes was also the co-founder and CEO of Cullinan Oncology, Inc., a publicly-traded oncology company, from September 2017 to October 2021. Prior to his operating roles, he spent 16 years on Wall Street, with positions at Brookside Capital, an operating division of Bain Capital, and Pyramis Global Advisors, a Fidelity Investments Company. Mr. Hughes served on the board of Radius Health, Inc. until its sale to Gurnet Point Capital and Patient Square Capital, and on the board of Translate Bio, Inc. until its acquisition by Sanofi. Thomas Burns, Senior Vice President, Finance and Chief Financial Officer Thomas Burns has served as Senior Vice President, Finance and Chief Financial Officer of XOMA Royalty since March 2017. He joined the company in August 2006 and has held various senior finance and accounting roles. Mr. Burns possesses over 25 years of experience in accounting and finance within both biotechnology and high-technology sectors. Before joining XOMA, he held multiple senior financial management positions at high-technology companies including Mattson Technology, IntruVert Networks (acquired by McAfee), Niku Corporation (acquired by Computer Associates), and Conner Technology. Bradley Sitko, Chief Investment Officer Bradley Sitko has been the Chief Investment Officer of XOMA Royalty since January 2023. From November 2019 to January 2023, he served as Managing Director, Strategic Finance, at RTW Investments, LP, a global investment firm focused on the biopharmaceutical and medical technology sectors, where he was responsible for royalty monetization, structured finance, and alternatives efforts. He also served as a board member of RTW Investments ICAV and was Chief Financial Officer of Ji Xing Pharmaceuticals Limited, a Shanghai-based biopharmaceutical company incubated by RTW Investments, LP. Prior to RTW, Mr. Sitko worked as a senior investment banker at MTS Health Partners.AI Analysis | Feedback
Here are the key risks to XOMA Royalty's business:- Risk of Partnered Drug Development Failure: XOMA Royalty's business model relies on acquiring rights to milestone and royalty payments from therapeutic candidates developed by its partners. As such, the company is highly susceptible to the clinical and regulatory success of these partnered drug candidates. A prime example of this risk materializing is the failed Phase 3 trial of ersodetug by XOMA's partner Rezolute, which led to a significant decrease in XOMA's stock value and the loss of anticipated milestone payments and revenue streams. Given that XOMA often targets early to mid-stage clinical assets, these investments inherently carry a higher risk of development failure.
- Financial Strength and High Debt Levels: XOMA's financial strength has been rated as poor, largely due to its elevated debt levels. An Altman Z-Score of -4.46 places the company in a "distress zone," suggesting a potential risk of bankruptcy within the next two years. While XOMA has secured non-dilutive financing, its overall financial health and ability to service its debt remain critical concerns, particularly given the inherent volatility of its revenue streams.
- Focus on Less Established Molecules and Investment Loss: Compared to larger competitors in the royalty aggregation space, XOMA Royalty focuses on acquiring rights to "less established molecules" and "low-key assets." This strategy, while potentially offering higher yields, inherently carries a greater risk of losing investments in underperforming assets. The mixed financial outcomes from certain assets in XOMA's portfolio, such as DSUVIA, illustrate the potential for such investment losses.
AI Analysis | Feedback
nullAI Analysis | Feedback
The addressable markets for XOMA Royalty's main products or services, which are royalty streams from therapeutic candidates, are as follows:
- DSUVIA (sufentanil sublingual tablet) for acute pain: The commercial market for DSUVIA has been withdrawn due to manufacturing constraints.
- OJEMDA™ (tovorafenib) for pediatric low-grade glioma (pLGG): The global market for pediatric glioma drugs is estimated at approximately USD 5 billion in 2024 and is projected to reach nearly USD 11 billion by 2034. North America holds the largest share of this market, accounting for about 42% of total revenue in 2024.
- MIPLYFFA™ (arimoclomol) for Niemann-Pick disease type C (NPC): The global Niemann-Pick Disease Type C market reached US$ 9.00 million in 2024 and is expected to reach US$ 923.57 million by 2033.
- Ersodetug for congenital hyperinsulinism (HI): The global congenital hyperinsulinism treatment market size was estimated at USD 192.20 million in 2024 and is expected to reach USD 302.41 million by 2032.
- Seralutunib for pulmonary arterial hypertension (PAH): The global pulmonary arterial hypertension market size was estimated at USD 8.02 billion in 2024 and is projected to reach USD 13.34 billion by 2033. North America maintains the largest share of 41.85% in 2024.
- Sildenafil Cream, 3.6% for female sexual arousal disorder: The global arousal disorder treatment market was valued at USD 7.5 billion in 2022 and is projected to reach USD 11.08 billion by 2030. The U.S. female sexual dysfunction treatment market is projected to reach an estimated value of USD 782.3 million by 2032.
- Hormone-free monthly intravaginal contraceptive: The global contraceptive market size was estimated at USD 31,178.9 million in 2024 and is projected to reach USD 44,039.4 million by 2030. North America held the largest global revenue share of 30.98% in 2023.
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for XOMA Royalty (XOMA) over the next 2-3 years:
- Increased Royalties from Currently Commercialized Products: Continued strong sales and market penetration of XOMA's existing commercial royalty assets are expected to drive recurring revenue growth. Specifically, VABYSMO® (faricimab), OJEMDA™ (tovorafenib), and MIPLYFFA™ (arimoclomol) have been highlighted as primary contributors to increased income.
- Milestone Payments from Advancing Pipeline Candidates: XOMA Royalty acquires economic rights to future milestone payments associated with partnered pre-commercial clinical candidates. The successful advancement of these assets through clinical trials and achievement of regulatory approvals are expected to trigger significant milestone payments. Upcoming key pipeline advancements include Zevra Therapeutics' arimoclomol for Niemann-Pick Type C, Rezolute Bio's ersodetug for congenital hyperinsulinism, and Gossamer Bio's seralutunib for pulmonary arterial hypertension, all of which have anticipated clinical readouts or regulatory submissions in the near term.
- Strategic Acquisitions of New Royalty and Milestone Interests: XOMA Royalty's business model centers on actively acquiring the rights to future potential milestone and royalty payments from therapeutic assets, including through whole company acquisitions. This strategy diversifies and expands their portfolio, adding new revenue streams. Recent examples include the acquisitions of Turnstone Biologics, HilleVax, and the expected acquisition of LAVA Therapeutics, as well as securing additional economics in mezagitamab.
AI Analysis | Feedback
Capital Allocation Decisions (Last 3-5 Years)
Share Repurchases
- XOMA's Board of Directors authorized a stock repurchase program of up to $50 million in January 2024, set to run through January 2027.
- During the first nine months of 2025, XOMA Royalty repurchased approximately 108,510 shares of its common stock for a total cost of $2.4 million.
Share Issuance
- As of March 13, 2025, the number of outstanding common shares was 11,978,717, an increase from 11,625,826 shares outstanding on March 4, 2024.
Outbound Investments
- In 2024, XOMA Royalty deployed $65 million to acquire new milestone and royalty assets.
- During the first six months of 2025, XOMA Royalty deployed $25.0 million to acquire additional assets for its royalty and milestone portfolio, including $20 million to acquire additional economics in mezagitamab from BioInvent International.
- In January 2025, XOMA completed a strategic acquisition of Pulmokine Inc. and its stake in the drug seralutinib for $20 million upfront, with potential milestone payments up to an additional $25 million.
Capital Expenditures
- Research and development expenses for the third quarter of 2025 were $69,000, significantly lower than $0.8 million in the corresponding period of the prior year, indicating minimal capital expenditures related to R&D.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| XOMA Royalty Earnings Notes | 12/16/2025 | |
| Would You Still Hold XOMA Royalty Stock If It Fell Another 30%? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 44.10 |
| Mkt Cap | 3.8 |
| Rev LTM | 251 |
| Op Inc LTM | 29 |
| FCF LTM | 21 |
| FCF 3Y Avg | 39 |
| CFO LTM | 32 |
| CFO 3Y Avg | 68 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 29.4% |
| Rev Chg 3Y Avg | 16.0% |
| Rev Chg Q | 7.9% |
| QoQ Delta Rev Chg LTM | 1.9% |
| Op Mgn LTM | 65.2% |
| Op Mgn 3Y Avg | 6.3% |
| QoQ Delta Op Mgn LTM | 3.7% |
| CFO/Rev LTM | 43.5% |
| CFO/Rev 3Y Avg | 41.6% |
| FCF/Rev LTM | 42.6% |
| FCF/Rev 3Y Avg | 23.9% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 3.8 |
| P/S | 14.9 |
| P/EBIT | 12.0 |
| P/E | 24.9 |
| P/CFO | 55.3 |
| Total Yield | 6.0% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 2.7% |
| D/E | 0.4 |
| Net D/E | 0.3 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -2.2% |
| 3M Rtn | -7.9% |
| 6M Rtn | 20.5% |
| 12M Rtn | 43.8% |
| 3Y Rtn | 25.0% |
| 1M Excs Rtn | -0.1% |
| 3M Excs Rtn | 0.8% |
| 6M Excs Rtn | 13.0% |
| 12M Excs Rtn | 32.0% |
| 3Y Excs Rtn | -43.9% |
Price Behavior
Price Behavior
| Market Price | $24.92 | |
| Market Cap ($ Bil) | 0.3 | |
| First Trading Date | 04/05/1989 | |
| Distance from 52W High | -37.3% | |
| 50 Days | 200 Days | |
| DMA Price | $27.66 | $29.46 |
| DMA Trend | up | down |
| Distance from DMA | -9.9% | -15.4% |
| 3M | 1YR | |
| Volatility | 74.6% | 55.4% |
| Downside Capture | 0.34 | 69.75 |
| Upside Capture | -181.83 | 54.93 |
| Correlation (SPY) | 7.8% | 28.2% |
XOMA Betas & Captures as of 1/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.75 | 0.05 | 0.60 | 0.97 | 0.82 | 0.78 |
| Up Beta | 4.30 | 7.52 | 3.27 | 3.04 | 1.03 | 1.09 |
| Down Beta | 0.50 | 2.01 | 2.49 | 2.13 | 0.75 | 0.79 |
| Up Capture | -266% | -293% | -145% | -13% | 45% | 24% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 8 | 21 | 32 | 68 | 128 | 372 |
| Down Capture | -339% | -226% | -45% | -42% | 77% | 80% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 12 | 20 | 29 | 57 | 119 | 373 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with XOMA | |
|---|---|---|---|---|
| XOMA | -3.3% | 55.4% | 0.15 | - |
| Sector ETF (XLV) | 6.7% | 17.3% | 0.22 | 28.8% |
| Equity (SPY) | 13.6% | 19.3% | 0.54 | 28.9% |
| Gold (GLD) | 69.7% | 24.7% | 2.11 | -5.2% |
| Commodities (DBC) | 7.1% | 16.6% | 0.24 | -0.3% |
| Real Estate (VNQ) | 4.4% | 16.5% | 0.09 | 25.7% |
| Bitcoin (BTCUSD) | -26.6% | 40.5% | -0.66 | 18.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with XOMA | |
|---|---|---|---|---|
| XOMA | -7.3% | 62.5% | 0.13 | - |
| Sector ETF (XLV) | 7.7% | 14.4% | 0.35 | 23.4% |
| Equity (SPY) | 14.4% | 17.0% | 0.67 | 23.1% |
| Gold (GLD) | 20.8% | 16.9% | 1.01 | -2.0% |
| Commodities (DBC) | 11.7% | 18.9% | 0.50 | 6.4% |
| Real Estate (VNQ) | 5.2% | 18.8% | 0.18 | 18.3% |
| Bitcoin (BTCUSD) | 16.0% | 57.4% | 0.49 | 12.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with XOMA | |
|---|---|---|---|---|
| XOMA | 2.1% | 67.7% | 0.32 | - |
| Sector ETF (XLV) | 10.8% | 16.5% | 0.54 | 28.5% |
| Equity (SPY) | 15.5% | 17.9% | 0.74 | 27.8% |
| Gold (GLD) | 15.4% | 15.5% | 0.83 | -3.0% |
| Commodities (DBC) | 7.9% | 17.6% | 0.37 | 9.6% |
| Real Estate (VNQ) | 6.0% | 20.7% | 0.26 | 20.4% |
| Bitcoin (BTCUSD) | 69.0% | 66.5% | 1.08 | 9.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/12/2025 | -2.5% | -4.9% | -26.9% |
| 8/13/2025 | 8.5% | 12.6% | 32.5% |
| 3/17/2025 | 0.8% | 1.0% | 0.3% |
| 11/7/2024 | -7.0% | -8.5% | -7.1% |
| 8/13/2024 | 14.4% | 27.1% | 17.3% |
| 3/8/2024 | -1.6% | 2.6% | 0.5% |
| 11/7/2023 | -6.4% | -8.5% | -6.8% |
| 8/8/2023 | -1.8% | -0.7% | -7.4% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 9 | 11 | 10 |
| # Negative | 10 | 8 | 9 |
| Median Positive | 2.3% | 5.0% | 17.6% |
| Median Negative | -3.2% | -5.3% | -11.6% |
| Max Positive | 14.4% | 27.1% | 32.5% |
| Max Negative | -7.0% | -27.9% | -26.9% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 08/13/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 03/17/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/13/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 03/08/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 03/09/2023 | 10-K |
| 09/30/2022 | 11/03/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| 03/31/2022 | 05/05/2022 | 10-Q |
| 12/31/2021 | 03/08/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Hughes, Owen | Chief Executive Officer | Direct | Buy | 12082025 | 25.05 | 100,000 | 2,505,000 | 2,555,100 | Form |
| 2 | Burns, Thomas M | SVP, Finance & CFO | Direct | Sell | 9232025 | 35.99 | 4,330 | 155,820 | 1,082,428 | Form |
| 3 | Sitko, Bradley | Chief Investment Officer | Direct | Buy | 7022025 | 25.39 | 2,000 | 50,780 | 178,873 | Form |
| 4 | Hughes, Owen | Chief Executive Officer | Direct | Sell | 5212025 | 25.38 | 25,637 | 650,667 | 1,591,351 | Form |
| 5 | Burns, Thomas M | SVP, Finance & CFO | Direct | Sell | 5212025 | 25.38 | 10,482 | 266,033 | 572,649 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.